Regeneron’s antibody cocktail is the latest COVID-19 drug to receive Emergency Use Authorization in the US, becoming the first therapy of this kind to become available.

The fight for dominance between Regeneron and Bayer’s big blockbuster ... and described it as “the first and only bispecific antibody targeting two distinct pathways in [neovascular age ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the ...

“We purchased Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biopharmaceutical company that was built on a foundation in basic scientific research and antibody development. The company has ...

To counter the decline in Eylea sales, Regeneron developed a higher dose ... The FDA issued a CRL for the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple ...

C5 Combo (pozelimab and cemdisiran) in complement-mediated diseases: Regeneron's differentiated siRNA and antibody combination approach has the potential to address multiple complement-mediated ...

US FDA revokes authorization for four COVID antibody drugs Healthcare & Pharmaceuticalscategory· December 23, 2024 Regeneron Pharmaceuticals has settled allegations that it misused a patented ...

He also highlighted Regeneron's eye care franchise and asthma treatment, as well as its experimental antibody cocktail President-elect Donald Trump received when he contracted Covid. Merck and ...

If you’re on the fence about investing in Regeneron Pharmaceuticals ... TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a ...